Drugs that contain Everolimus
1. Afinitor patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778962 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(1 year, 9 months ago) | |
| US8436010 | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(1 year, 9 months ago) | |
|
US8778962 (Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(1 year, 3 months ago) | |
|
US8436010 (Pediatric) | NOVARTIS | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(1 year, 3 months ago) | |
| US8410131 | NOVARTIS | Cancer treatment |
Nov, 2025
(1 year, 11 months from now) | |
|
US8410131 (Pediatric) | NOVARTIS | Cancer treatment |
May, 2026
(2 years from now) | |
| US9006224 | NOVARTIS | Neuroendocrine tumor treatment |
Jul, 2028
(4 years from now) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Feb 26, 2023 |
Market Authorisation Date: 30 March, 2009
Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Treatment of ...
Dosage: TABLET;ORAL
AFINITOR family patents
2. Afinitor Disperz patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US8778962 | NOVARTIS PHARM | Treatment of solid tumors with rapamycin derivatives |
Feb, 2022
(1 year, 9 months ago) | |
|
US8778962 (Pediatric) | NOVARTIS PHARM | Treatment of solid tumors with rapamycin derivatives |
Aug, 2022
(1 year, 3 months ago) | |
| US8617598 | NOVARTIS PHARM | Pharmaceutical compositions comprising colloidal silicon dioxide |
Sep, 2022
(1 year, 2 months ago) | |
|
US8617598 (Pediatric) | NOVARTIS PHARM | Pharmaceutical compositions comprising colloidal silicon dioxide |
Mar, 2023
(8 months ago) | |
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| Orphan Drug Exclusivity (ODE) | Apr 10, 2025 |
Market Authorisation Date: 29 August, 2012
Treatment: Treatment of patients with tuberous sclerosis complex (tsc) who have subependymal giant cell astrocytoma (sega) that requires therapeutic intervention but cannot be curatively resected.; Adjunctive tr...
Dosage: TABLET, FOR SUSPENSION;ORAL
AFINITOR DISPERZ family patents